TSG101 (Tumor Susceptibility 101)

The EDDS markedly decreases processing time, cost, and technological complexity by obviating the necessity for traditional EVs isolation techniques such as ultracentrifugation or chromatography. This integrated platform facilitates direct EVs disruption and multiplexed biomarker identification within a singular workflow, providing a robust instrument for minimally invasive cancer diagnostics and advancing broader clinical applications in liquid biopsy.

Accordingly, silencing RAB4A significantly increased the fusion of multivesicular bodies with the plasma membrane followed by EV secretion, suggesting that TGF-β-induced RAB4A acts as a negative feedback regulator of EV release. Our findings reveal a novel mechanism by which RAB4A modulates TGF-β-driven EV production by cancer cells.

Finally, the protein levels of SIAH1 were found to be inversely correlated with TSG101 in human HCC tissues. In summary, TSG101 is up-regulated in human HCC tissues and promotes the migration and invasion of HCC cells by inducing SIAH1 auto-ubiquitination and degradation.

At the mechanistic level, the RIP assay (anti-IL-4 antibody pull-down) suggests that LINC01614 may directly interact with IL-4. In summary, this study preliminarily reveals the mechanism by which LINC01614 promotes Treg differentiation and M2 polarization through the exosome pathway to regulate the immune microenvironment of gastric cancer, providing a theoretical basis for targeting LINC01614 to enhance immunotherapy.

Hypoxia induces distinct exosomal miRNA signatures in skeletal muscle, regulating genes involved in differentiation, migration, and stress response. These findings suggest that exosome-mediated miRNA signaling contributes to hypoxia-driven muscle adaptation and intercellular communication.

Engineered exosomes carrying anti-angiogenic, autophagy-inhibiting, or pro-apoptotic molecules can reprogram the tumor microenvironment and activate both the intrinsic mitochondrial and extrinsic ligand-mediated apoptotic pathways. Collectively, current evidence underscores the potential of strategically modulating endogenous exosome biogenesis and harnessing exogenous engineered therapeutic exosomes to interrupt the angiogenic and autophagic circuits that underpin therapy resistance, ultimately leading to the induction of apoptotic cell death in GBM.

Moreover, this review reveals the challenges in the contemporary research that are of critical importance: optimization of large-scale production and purification of ASC-Exos to provide uniformity in the clinical use; full clarification of the molecular processes that underlie ASC-Exos-mediated effects (e.g., metabolic reprogramming control in tumors); and the absence of detailed preclinical and clinical data on the long-term safety and efficacy. Finally, the review would serve as a valuable resource to developing fundamental research in the field of ASC-Exos and increasing the pace of its clinical application, especially when used together in conjunction with more sophisticated methods of drug delivery and tissue regeneration, to achieve new prospects in the treatment of incurable diseases and repair tissue in regenerative medicine.

The presence of DAO in peroxisomes, autophagosomes, lysosomes, and exosomes indicated diverse intracellular localization within CPECs. This distribution may enable efficient metabolism of blood-derived D-serine in CPECs.

More genetic analyses indicated that BAF1 and LEM2 contribute to safeguarding of telomeres during nuclear envelope reassembly. Because defects in nuclear envelope dynamics and chromatin-membrane coupling are hallmarks of disorders associated with nuclear deformation and fragility, including aging and cancer, our findings contribute a new angle into these conditions and suggest potential targets for selectively modulating telomere maintenance pathways.

Among the previously identified EV cargo, HIF1a and KAT2B were found to be expressed in RB tumors, indicating their potential as biomarkers. KAT2B, previously identified as EV cargo, showed expression in tumor tissue, validating its biomarker potential.

EA of BL40 and BL23 can significantly up-regulate the expressions of Pax7, MyoD, MyoG and MyHC in the injured multifidus muscle, and promote the regeneration and repair of lumbar multifidus muscle, which may be related to its functions in promoting the release of exosomes in the acupoint area.

This proof-of-concept study suggests an impact of ABT on the urinary EV-microRNA cargo and yields comprehensive findings into surface markers of urinary EVs. While the adoption of urinary EV-associated microRNAs in routine doping tests requires further exploration, these data serve as a valuable basis for a variety of subsequent investigations.